EU-MEDICAL_DEVICES_REGULATION-ANX_I_SEC_10
EU-MEDICAL_DEVICES_REGULATION-ANX_I_SEC_10
Medical Devices Regulation - Hazardous Substances
EU. Hazardous Substances for Purposes of Medical Devices Regulation 2017/745/EU, 5 May 2017, as amended by Regulation 2020/561/EU, 24 April 2020
This list contains hazardous substances for purposes of the Medical Devices Regulation (MDR), based on the legislation's Annex I general safety and performance requirements, including for chemical, physical and biological properties. Specifically, the non-exhaustive database is derived from: Table 3 of Annex VI to CLP, REACH Candidate List of SVHCs, and Directive 2000/54/EC's Annex III (Biological Agents list).
Last updated 26 srpnja 2024. Database contains 4917 unique substances/entries.
Filter the list
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
244-058-7
|
20816-12-0
|
Acute Tox. 2; Acute Tox. 1; Skin Corr. 1B |
Details | |||
|
237-560-2
|
13840-56-7
|
Repr. 1B |
R Toxic for reproduction (article 57c) |
Details | ||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
show/hide
Hydrogen [metasilicato(2-)-O](2-methoxyethyl)mercurate(1-)
EC / List no:
264-920-6
| CAS no:
64491-92-5
Mercury, (3-(2,5-dioxo-1-pyrrolidinyl)-2-methoxypropyl)hydroxy-, compd. with 3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione (1:1)
EC / List no:
-
| CAS no:
747-23-9
[2,2',2''-nitrilotri(ethanol)-N,O,O',O'']phenylmercury lactate
EC / List no:
245-581-3
| CAS no:
23319-66-6
Bis(acetato-O)[μ-[1,3-dioxane-2,5-diylbis(methylene)-C:C',O,O']]dimercury
EC / List no:
281-717-8
| CAS no:
84029-43-6
Mercury, (3-((((3-carboxy-1-oxopropyl)amino)carbonyl)amino)-2-methoxypropyl)hydroxy-
EC / List no:
-
| CAS no:
140-20-5
Mercury, phenyl((2-phenyldiazenecarbothioic acid-kappaS) 2-phenylhydrazidato-kappaN2)-
EC / List no:
-
| CAS no:
12406-51-8
Hydrogen triiodomercurate(1-), compound with 3-methyl-3H-benzothiazol-2-imine (1:1)
EC / List no:
276-613-4
| CAS no:
72379-35-2
(4-((4-(Dimethylamino)phenyl)azo)phenyl)mercuric acetate
EC / List no:
631-561-5
| CAS no:
19447-62-2
[2,5-dichloro-3,6-dihydroxy-2,5-cyclohexadiene-1,4-dionato(2-)-O1,O6]mercury
EC / List no:
251-672-9
| CAS no:
33770-60-4
Butanoic acid, 4-((((2-methoxypropyl)amino)carbonyl)amino)-4-oxo-, mercury complex
EC / List no:
-
| CAS no:
72-58-2
Hydrogen μ-hydroxy[μ-[orthoborato(3-)-O:O']]diphenyldimercurate(1-)
EC / List no:
304-637-8
| CAS no:
94277-53-9
Cyclopentanecarboxylic acid, 3-(((3-mercapto-2-methoxypropyl)amino)carbonyl)-2,2,3-trimethyl-, mercury complex
EC / List no:
-
| CAS no:
76-31-3
(2',7'-dibromo-3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-4'-yl)hydroxymercury
EC / List no:
259-779-2
| CAS no:
55728-51-3
Sodium [3-[[(3-carboxylatopropionamido)carbonyl]amino]-2-methoxypropyl]hydroxymercurate(1-)
EC / List no:
231-532-3
| CAS no:
7620-30-6
Turpentine, Venice, sulfurized, reaction products with hydrogen tetrachloroaurate(-1), sulfurized turpentine oil and mercurous nitrate, mixed with mercurous oxide
EC / List no:
293-784-0
| CAS no:
91082-69-8
Hydrogen [3-[(α-carboxylato-o-anisoyl)amino]-2-hydroxypropyl]hydroxymercurate(1-)
EC / List no:
247-796-8
| CAS no:
26552-50-1
2-hydroxy-5-(1,1,3,3-tetramethylbutyl)phenylmercury acetate
EC / List no:
209-534-0
| CAS no:
584-18-9
[μ-[[4,4'-(oxydiethylene) bis(dodecenylsuccinato)](2-)]]diphenyldimercury
EC / List no:
299-418-6
| CAS no:
93882-20-3
Tetrakis(acetato-O)[μ4-(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthene]-2',4',5',7'-tetrayl)]tetramercury
EC / List no:
259-075-5
| CAS no:
54295-90-8
Benzenesulfonic acid, 4-hydroxy-3,5-diiodo-, mercury(2+) salt (1:1)
EC / List no:
-
| CAS no:
515-43-5
Mercurate(1-), [dodecenylbutanedioato(2-)-O']phenyl-, hydrogen
EC / List no:
304-575-1
| CAS no:
94276-88-7
Mercury, (acetato-kappaO)(3-(chloromethoxy-kappaO)propyl-kappaC)-
EC / List no:
-
| CAS no:
1319-86-4
Diphenyl[μ-[(tetrapropenyl)succinato(2-)-O:O']]dimercury
EC / List no:
248-355-2
| CAS no:
27236-65-3
Bis(acetato-O)[μ-(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthene]-2',7'-diyl)]dimercury
EC / List no:
222-673-1
| CAS no:
3570-80-7
[μ-[(oxydiethylene but-2-enedioato)(2-)]]diphenyldimercury
EC / List no:
301-791-8
| CAS no:
94070-92-5
|
-
|
-
|
Acute Tox. 2; Acute Tox. 1; STOT RE 2 |
Details | ||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
215-235-6
|
1314-41-6
|
R Toxic for reproduction (article 57c) |
Details | |||
|
-
|
-
|
P Parasites |
Details | |||
|
-
|
-
|
P Parasites |
Details | |||
|
-
|
-
|
P Parasites |
Details | |||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
214-197-8
|
1113-02-6
|
Acute Tox. 3; Acute Tox. 4 |
Details | |||
|
An inorganic pigment that is the reaction product of high temperature calcination in which nickel (II) oxide and silicon oxide in varying amounts are homogeneously and ionically interdiffused to form a crystalline matrix of olivine. Its composition may include any one or a combination of the modifiers alkali or alkaline earth halides.
|
271-112-7
|
68515-84-4
|
Carc. 1A; STOT RE 1; Skin Sens. 1 |
Details | ||
|
-
|
-
|
C Carcinogenic (article 57a) |
Details | |||
|
show/hide
|
700-960-7
|
-
|
VPVB very Persistent and very Bioaccumulative (article 57e) |
Details | ||
|
-
|
-
|
Skin Corr. 1A; STOT SE 3 |
Details | |||
|
213-853-0
|
1034-01-1
|
Acute Tox. 4; Skin Sens. 1 |
Details | |||
|
247-761-7
|
26530-20-1
|
Acute Tox. 2; Acute Tox. 3; Skin Corr. 1; Eye Dam. 1; Skin Sens. 1A |
Details | |||
|
H112339
|
413-550-5
|
-
|
Skin Irrit. 2; Eye Dam. 1 |
Details | ||
|
PROCION BRILLIANT ORANGE H-EXL; S156745
|
412-960-1
|
148878-21-1
|
Eye Dam. 1; Skin Sens. 1 |
Details | ||
|
204-677-5
|
124-07-2
|
Skin Corr. 1C |
Details | |||
|
203-892-1
|
111-65-9
|
Flam. Liq. 2; Asp. Tox. 1; Skin Irrit. 2; STOT SE 3 |
Details | |||
|
209-136-7
|
556-67-2
|
Repr. 2 |
PBT Persistent, Bioaccumulative and Toxic (article 57d) VPVB very Persistent and very Bioaccumulative (article 57e) |
Details | ||
|
204-695-3
|
124-30-1
|
Asp. Tox. 1; STOT RE 2; Skin Irrit. 2; Eye Dam. 1 |
Details | |||
|
202-422-2
|
95-47-6
|
Flam. Liq. 3; Acute Tox. 4; Skin Irrit. 2 |
Details | |||
|
202-429-0
|
95-53-4
|
Carc. 1B; Acute Tox. 3; Eye Irrit. 2 |
C Carcinogenic (article 57a) |
Details | ||
|
show/hide
Disodium 3,3'-[(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[2,4-diamino-5-methylbenzenesulphonate]
EC / List no:
229-024-1
| CAS no:
6405-94-3
Tetrasodium 3,3'-[(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[4,5-dihydroxynaphthalene-2,7-disulphonate]
EC / List no:
218-432-5
| CAS no:
2150-54-1
Benzamide, 3,3'-((3,3'-dimethyl(1,1'-biphenyl)-4,4'-diyl)bis(imino(1-acetyl-2-oxo-2,1-ethanediyl)-2,1-diazenediyl))bis(4-methyl-
EC / List no:
-
| CAS no:
64441-14-1
3,3'-[(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis[imino(1-acetyl-2-oxoethane-1,2-diyl)azo]]bis[bis(3-aminopropyl)(p-methoxybenzyl)methylammonium] dichloride
EC / List no:
255-154-3
| CAS no:
40948-42-3
2,2'-[(3,3'-dimethyl-4,4'-biphenylylene)bis(azo)]bis[4-(1,1,3,3-tetramethylbutyl)phenol]
EC / List no:
230-616-7
| CAS no:
7218-82-8
Tetrasodium 3,3'-[(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[5-amino-4-hydroxynaphthalene-2,7-disulphonate]
EC / List no:
200-786-7
| CAS no:
72-57-1
N,N'-(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis[3-oxobutyramide], disodium salt
EC / List no:
271-328-1
| CAS no:
68540-94-3
2,2'-[(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[4-nonylphenol]
EC / List no:
268-048-7
| CAS no:
67990-27-6
Tetrasodium 6,6'-((3,3'-dimethyl-(1,1'-biphenyl-4,4'diyl)bis(azo)bis(4-amino-5-hydroxy-1,3-naphthalenedisulphonate)
EC / List no:
206-242-5
| CAS no:
314-13-6
N,N'-(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis[2-[(2,4-dichlorophenyl)azo]-3-oxobutyramide]
EC / List no:
227-783-3
| CAS no:
5979-28-2
Disodium 3,3'-((3,3'-dimethyl(1,1'-biphenyl)-4,4'-diyl)bis(azo)bis(4-aminonaphthalene-1-sulphonate)
EC / List no:
213-594-3
| CAS no:
992-59-6
N,N'-(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis(3-hydroxynaphthalene-2-carboxamide)
EC / List no:
223-007-2
| CAS no:
3692-05-5
2,2'-[(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[3-oxo-N-phenylbutyramide]
EC / List no:
228-789-9
| CAS no:
6358-88-9
|
-
|
-
|
Carc. 1B |
Details | ||
|
210-418-7
|
615-28-1
|
Carc. 2; Muta. 2; Acute Tox. 3; Acute Tox. 4; Eye Irrit. 2; Skin Sens. 1 |
Details | |||
|
202-430-6
|
95-54-5
|
Carc. 2; Muta. 2; Acute Tox. 3; Acute Tox. 4; Eye Irrit. 2; Skin Sens. 1 |
Details | |||
|
201-855-4
|
88-74-4
|
Acute Tox. 3; STOT RE 2 |
Details | |||
|
434-350-4
|
103122-66-3
|
Flam. Liq. 3; Carc. 1B; Muta. 1B; Acute Tox. 4; STOT RE 2; Skin Sens. 1 |
Details | |||
|
432-750-3
|
109202-58-6
|
Carc. 1B; Muta. 1B; Acute Tox. 4; STOT RE 2; Skin Sens. 1 |
Details | |||
|
ETA; ETA 50 (50 %IGE ZUBEREITUNG); O-ETHYLHYDROXYLAMINE
|
402-030-3
|
624-86-2
|
Flam. Liq. 2; Acute Tox. 3; STOT RE 1; Eye Irrit. 2; Skin Sens. 1 |
Details | ||
|
218-276-8
|
2104-64-5
|
Acute Tox. 1; Acute Tox. 2 |
Details | |||
|
show/hide
Tetrasodium 3,3'-[(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[5-(acetylamino)-4-hydroxynaphthalene-2,7-disulphonate]
EC / List no:
267-711-8
| CAS no:
67906-44-9
Tetrasodium 4,4'-[(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[3-hydroxynaphthalene-2,7-disulphonate]
EC / List no:
265-533-5
| CAS no:
65151-33-9
2,7-Naphthalenedisulfonic acid, 3,3'-((3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)bis(2,1-diazenediyl))bis(5-amino-4-hydroxy-, lithium sodium salt (1:3:1)
EC / List no:
-
| CAS no:
75752-17-9
Tetrasodium 6,6'-[(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[4-amino-5-hydroxynaphthalene-1,3-disulphonate]
EC / List no:
220-026-8
| CAS no:
2610-05-1
2-Naphthalenecarboxamide, N,N'-(3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)bis(3-hydroxy-, disodium salt
EC / List no:
-
| CAS no:
52735-88-3
6,6'-[(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[4-amino-5-hydroxynaphthalene-1,3-disulphonic] acid
EC / List no:
223-333-5
| CAS no:
3841-14-3
2,2'-[(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[3-oxo-N-phenylbutyramide]
EC / List no:
229-388-1
| CAS no:
6505-28-8
Copper, 3,3'-((3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)bis(2,1-diazenediyl))bis(5-amino-4-hydroxy-2,7-naphthalenedisulfonate) morpholine ammonium lithium sodium complexes
EC / List no:
-
| CAS no:
96591-22-9
3,3'-[(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)diazo]bis[5-amino-4-hydroxynaphthalene-2,7-disulphonic] acid, sodium salt, compound with 2,2'-iminodiethanol
EC / List no:
273-433-8
| CAS no:
68966-43-8
3,3'-dihydroxy-N,N'-(3,3'-dimethoxybiphenyl-4,4'-diyl)di-2-naphthamide
EC / List no:
202-108-5
| CAS no:
91-92-9
5,5'-(3,3'-Dimethoxy(1,1'-biphenyl)-4,4'-diyl)bis(1-(4-nitrophenyl)-3-phenylformazan)
EC / List no:
-
| CAS no:
63469-14-7
3,3'-(3,3'-dimethoxy-4,4'-biphenylene)bis(2,5-diphenyl-2H-tetrazolium) chloride
EC / List no:
217-488-8
| CAS no:
1871-22-3
2,2'-[(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[N-(2-methylphenyl)-3-oxobutyramide]
EC / List no:
230-458-9
| CAS no:
7147-42-4
Disodium 4,4'-[(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[iminocarbonyl(2-hydroxy-4,1-phenylene)azo]]bis(3-hydroxynaphthalene-1-sulphonate)
EC / List no:
274-498-5
| CAS no:
70247-69-7
N,N'-(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[3-oxobutyramide]
EC / List no:
223-873-1
| CAS no:
4104-12-5
Tetrasodium 3,3'-[(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[5-amino-4-hydroxynaphthalene-2,7-disulphonate]
EC / List no:
219-385-3
| CAS no:
2429-74-5
2,2'-[(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[N-(2,4-dimethylphenyl)-3-oxobutyramide]
EC / List no:
229-920-2
| CAS no:
6837-37-2
Butanamide, 2,2'-((3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)bis(2,1-diazenediyl))bis(N-(chlorophenyl)-3-oxo-
EC / List no:
-
| CAS no:
72845-99-9
3,3'-[(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)diazo]bis[5-amino-4-hydroxynaphthalene-2,7-disulphonic] acid, sodium salt
EC / List no:
273-439-0
| CAS no:
68966-50-7
Disodium 2,2'-[(3,3'-dimethoxy-4,4'-biphenylylene)bis[azo(methylimino)]]di(ethanesulphonate)
EC / List no:
241-085-6
| CAS no:
17011-51-7
2,2'-[(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[N-(4-chlorophenyl)-3-oxobutyramide]
EC / List no:
241-469-3
| CAS no:
17453-73-5
2,7-Naphthalenedisulfonic acid, 3,3'-((3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)bis(2,1-diazenediyl))bis(5-amino-4-hydroxy-, lithium sodium salt (1:2:2)
EC / List no:
-
| CAS no:
75659-73-3
Tetrasodium 2,2'-[(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[azo(2-amino-5-hydroxy-7-sulphonato-6,1-naphthylene)azo]]bis[5-nitrobenzoate]
EC / List no:
274-429-9
| CAS no:
70210-33-2
2,7-Naphthalenedisulfonic acid, 3,3'-((3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)bis(2,1-diazenediyl))bis(5-amino-4-hydroxy-, lithium sodium salt (1:1:3)
EC / List no:
-
| CAS no:
75659-72-2
4,4'-[(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[3-hydroxy-N-(2-methoxyphenyl)naphthalene-2-carboxamide]
EC / List no:
226-614-0
| CAS no:
5437-88-7
5,5'-diphenyl-3,3'-bis(4-nitrophenyl)-2,2'-(3,3'-dimethoxybiphenyl-4,4'-ylene)ditetrazolium dichloride
EC / List no:
206-067-4
| CAS no:
298-83-9
4,4'-[(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[2,4-dihydro-5-methyl-2-(p-tolyl)-3H-pyrazol-3-one]
EC / List no:
229-986-2
| CAS no:
6883-91-6
4,4'-[(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[2,4-dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one]
EC / List no:
229-389-7
| CAS no:
6505-29-9
Tetralithium 3,3'-[(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[5-amino-4-hydroxynaphthalene-2,7-disulphonate]
EC / List no:
275-603-7
| CAS no:
71550-22-6
Benzoic acid, 4,4'-((3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)bis(2,1-diazenediyl(2-acetyl-1-oxo-2,1-ethanediyl)imino))bis-, 1,1'-dibutyl ester
EC / List no:
-
| CAS no:
820212-95-1
3,3'-(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[2,5-bis(p-nitrophenyl)-2H-tetrazolium] dichloride
EC / List no:
214-665-1
| CAS no:
1184-43-6
1-Naphthalenesulfonic acid, 3,3'-((3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)bis(2,1-diazenediyl))bis(4-hydroxy-, lithium sodium salt (1:1:1)
EC / List no:
-
| CAS no:
75673-35-7
Tetrasodium 3,3'-[(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[4,5-dihydroxynaphthalene-2,7-disulphonate]
EC / List no:
224-091-3
| CAS no:
4198-19-0
1-Naphthalenesulfonic acid, 3,3'-((3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)bis(2,1-diazenediyl))bis(4-hydroxy-, lithium salt (1:2)
EC / List no:
-
| CAS no:
75673-34-6
3,3'-(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[5-[4-(aminothioxomethyl)phenyl]-2-(p-nitrophenyl)-2H-tetrazolium] dichloride
EC / List no:
253-257-8
| CAS no:
36889-43-7
Disodium 3,3'-[(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis(4-hydroxynaphthalene-1-sulphonate)
EC / List no:
219-382-7
| CAS no:
2429-71-2
4,4'-[(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[3-hydroxy-N-phenylnaphthalene-2-carboxamide]
EC / List no:
233-354-1
| CAS no:
10127-03-4
|
-
|
-
|
Carc. 1B |
Details | ||
|
202-423-8
|
95-48-7
|
Acute Tox. 3; Skin Corr. 1B |
Details | |||
|
227-534-9
|
5873-54-1
|
Carc. 2; Acute Tox. 4; STOT RE 2; Eye Irrit. 2; STOT SE 3; Skin Irrit. 2; Resp. Sens. 1; Skin Sens. 1 |
Details | |||
|
221-817-0
|
3244-90-4
|
Acute Tox. 4 |
Details | |||
|
KENODOX
|
404-300-6
|
116753-76-5
|
Org. Perox. C |
Details | ||
|
ASIL-322; OS-5200
|
421-870-1
|
156145-66-3
|
Repr. 2; Acute Tox. 4; STOT RE 2 |
Details | ||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
VULKANISATIONSBESCHLEUNIGER VP KA 9124
|
404-380-2
|
110799-28-5
|
Skin Sens. 1 |
Details | ||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
-
|
2163-79-3
|
Acute Tox. 4 |
Details | |||
|
213-589-6
|
991-42-4
|
Acute Tox. 4 |
Details | |||
|
932-998-7
|
-
|
ENDE Endocrine disrupting properties (Article 57(f) - environment) |
Details | |||